Video

Dr. Costa Discusses Ongoing Research Efforts in TNBC

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.

Ricardo Costa, MD, MSc, medical oncologist, Department of Breast Oncology, Clinical Investigator Track, Moffitt Cancer Center, discusses ongoing research efforts in triple-negative breast cancer (TNBC).

Although drug development has not moved as rapidly in TNBC as it has in HER2-positive breast cancer, significant research efforts are underway for patients with TNBC, Costa says. Notably, immunotherapy remains an area of research to improve anticancer activity without compromising safety in this patient population, Costa explains. Moreover, immunotherapy could minimize the use of chemotherapy in TNBC, Costa adds.

Additionally, investigational antibody-drug conjugates (ADCs) are in clinical development, Costa says. These agents could offer an alternative option to the ADC sacituzumab govitecan-hziy (Trodelvy), which received a full approval on April 7, 2021, by the FDA for the treatment of patients with unresectable locally advanced or metastatic TNBC who have received at least 2 prior systemic therapies, including one for metastatic disease.

Additionally, PARP inhibitors could play a significant role in the adjuvant treatment of patients with TNBC who harbor germline BRCA mutations, Costa concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity